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Metformin mitigates the impaired development of
skeletal muscle in the offspring of obese mice
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Background: Maternal obesity is linked with offspring obesity and type 2 diabetes. Skeletal muscle (SM) insulin resistance is
central to the development of diabetes. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is inhibited in SM of
fetuses born to obese mothers.
Objective: The aim of this study was to evaluate the effect of maternal metformin administration on AMPK activity and reversion
of adverse changes in offspring SM of obese mice.
Design: Female weanling C57BL/6J mice received either control diet (CON, 6 mice) or high-fat diet (HFD; OB, 12 mice) for 8
weeks before mating. After mating, mice continued receiving their respective CON or OB diets. In addition, 6 of those 12 mice
fed with fat diet also received metformin administration (2mg per ml in drinking water) throughout gestation and lactation
(MET). After weaning at postnatal 21 days, offspring were fed a HFD to mimic a postnatal obesogenic environment until
necropsy.
Results: Mothers receiving the fat diet developed obesity. OB offspring showed higher adiposity than CON and MET offspring.
AMPK phosphorylation was lower in SM of OB offspring. b-Catenin and myogenic regulatory factors, MyoD and myogenin, were
downregulated in OB muscle, whereas the adipogenic marker, peroxisome proliferator-activated receptor-g, was upregulated
compared with CON muscle. Metformin administration prevented these changes in OB offspring SM. OB but not MET offspring
demonstrated glucose intolerance. Mitochondrial content decreased, and activities of citrate synthase and b-hydroxyacyl-CoA
dehydrogenase also decreased in OB offspring SM, whereas they were recovered in MET offspring SM.
Conclusion: Maternal metformin administration improves SM development in OB offspring.
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Introduction
Obesity and type 2 diabetes are increasing at alarming rates,
even in teenagers and infants.1,2 At the same time, the
prevalence of overweight and obese women of childbearing
age is a growing public health concern.3 Western high-
energy diets combined with maternal obesity (MO) represent
a special problem that can result in harmful, persistent
phenotypic outcomes in offspring, including predisposition
to obesity and diabetes.4–7 Although accumulating evidence
from both epidemiological studies and animal studies shows
that MO predisposes offspring to obesity and diabetes,6,8,9
the causative mechanisms have not been elucidated.
Skeletal muscle (SM) is a potential target for antiobese and
antidiabetic therapies because it constitutes about 40–50% of
body mass and is the main peripheral tissue responsive to
insulin-stimulated uptake of glucose and fatty acids.10
Development of insulin resistance in SM is an essential step
in the development of type 2 diabetes.11–13 The fetal stage is
crucial for SM development, because no net increase in the
number of muscle fibers occurs after birth.14
Fetal SM contains a large number of pluripotent cells.
Although the majority of these cells differentiate into muscle
fibers through myogenesis, a portion becomes adipocytes.14
The canonical Wnt/b-catenin signaling pathway is essential
for myogenesis.15,16 Enhancing Wnt/b-catenin signaling
increases expression of myogenic regulatory factors, includ-
ing Myf5 and MyoD,17–19 whereas downregulating Wnt/
b-catenin signaling pathway promotes adipogenesis by
enhancing the expression of peroxisome proliferator-
activated receptor-g (PPAR-g), a key regulator of adipogenesis.20
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adipocytes, an event linked to SM insulin resistance.10,21 Thus,
impairment of fetal SM development will predispose offspring
to diabetes and obesity in later life.14
Adenosine monophosphate (AMP)-activated protein kinase
(AMPK) is a master controller of energy metabolism in
SM.22,23 AMPK controls SM development by enhancing the
insulin signaling pathway24 and inhibiting adipo-
genesis,10,25,26 both of which link to SM insulin resistance.
Activation of AMPK promotes myogenesis, whereas inhibition
promotes adipogenesis.9,27 Metformin is the most common
drug currently in use for treating type 2 diabetes. Metformin’s
activity is mainly mediated by AMPK.28–30 Using a maternal
obese sheep model, we have showed that MO downregulates
AMPK activity in fetal SM, which is expected to have
profound impact on glucose uptake, insulin signaling and
properties of fetal and offspring SM.9 Based on these findings,
we hypothesized that activation of fetal SM AMPK by
maternal metformin administration would prevent the
changes in fetal and offspring SM properties that result from
exposure to MO. The objective of the present study was to
investigate the effects of metformin administration to obese
mothers on offspring SM composition and to assess the
importance of AMPK in the development of SM.
Materials and methods
Care and use of animals
Weaning C57BL/6J mice (Charles River Laboratories,
Wilmington, MA, USA) were maintained according to the
standard protocols approved by the University of Wyoming
Animal Use and Care Committee. Mice were housed two per
cage under a 12-h light/dark cycle (from 0630 to 1830
hours), with ad libitum access to diet and water. At 4 weeks of
age, females were randomized to receive either a control diet
(D12450B) with 10% energy from fat (CON) or a high-fat diet
(HFD; D12451) with 45% energy from fat for 8 weeks.
Control diet (D12450B, a starch, casein and sucrose-based
diet containing protein 19.2%, carbohydrate 67.3%, fat 4.3%
and vitamins 1.0%, 3.85 kcal g1) and high-energy diet
(D12451, a lard and sucrose-based diet containing protein
24.0%, carbohydrate 41.0%, fat 24.0% and vitamins 1.0%,
4.73 kcal g1) were purchased from Research Diets (New
Brunswick, NJ, USA). At 3 months of age, mice (6 CON mice
and 12 high-fat-fed mice) were housed individually and
bred. Following mating, all mice continued to receive their
respective diets until their litters were weaned. The 12 high-
fat-fed mice were further separated into two groups, with one
group (n¼6) receiving metformin (Spectrum Chemical MFG
Corp., New Brunswick, NJ, USA) administration (2mg per ml
in the drinking water, about 350mgkg1 per day, MET)
throughout pregnancy and lactation and the other group
(n¼ 6) supplied with normal drinking water (OB).
The dosage of metformin is based on a previous study.31
The litter size was normalized to six mice per litter. Body
weight (BW) and diet intake of dams and offspring were
monitored twice per week.
At weaning, maternal mice were killed, and serum was
collected for blood profile analyses. The maternal carcasses
were grounded, and the fat content was analyzed using Folch
extraction method.32 After weaning, all offspring were fed
with the HFD (D12451) to mimic a postnatal obesogenic
environment until necropsy at 60 days of age.
A separate cohort of 12 female mice were assigned to CON,
OB and MET groups (n¼4) and treated as described above.
Offspring male mice were used for glucose tolerance test.
Sample collection
Offspring were killed on postnatal day 1 (two mice per litter
were killed), day 15 (one male per litter) and day 60 (one
male per litter). Each mouse was skinned and eviscerated.
Owing to the small size of the offspring, the muscle from the
whole hind (after removing skin, bone and visible connec-
tive tissue and fat) was collected from postnatal day-1 mice
(muscles from 2 mice per litter were pooled) and day-15 male
mice (1 mouse per litter, n¼6 per treatment), frozen in
liquid N2 and stored at 80 1C for further analyses. For
postnatal day-60 mice, gastrocnemius muscle and gonadal
fat from males (n¼6 per group) were separated, weighed and
collected. Also, a section (from first to last lumbar vertebrae)
of trunk from day-1 and -15 mice was embedded in OCT
compound (Sakura Fineteck USA Inc., Torrance, CA, USA),
frozen in liquid N2 and stored in 80 1C for histological
examination of muscle structure.
Antibodies
Antibodies against AMPKa (cat. number 2532), phospho-
AMPKa at Ser172 (cat. number 2535) and b-catenin (cat.
number 9587) were purchased from Cell Signaling (Danvers,
MA, USA). Antibody against MyoD (cat. number 5117) was
purchased from GenScript Corporation (Piscataway, NJ,
USA). Antibody against myogenin was obtained from the
Developmental Studies Hybridoma Bank (University of Iowa,
Iowa City). Antibody against PPAR-g (cat. number DB134)
was purchased from Delta Biolabs (Gilroy, CA, USA). Anti-
body against glyceraldehyde 3-phosphate dehydrogenase
was purchased from Ambion Inc. (Austin, TX, USA).
Secondary antibodies were purchased from LI-COR Bio-
sciences (Lincoln, NE, USA).
Immunoblotting analysis
Frozen muscle samples (0.1 g) were homogenized in 500 ml
extraction buffer containing 20mM Tris-HCl (pH 7.4), 2%
SDS, 1% Triton X-100, 5.0mM EDTA, 5.0mM EGTA, 1mM
DTT, 100mM NaF, 2mM sodium vanadate, 0.5mM phenyl-
methylsufonyl fluoride, 10 ml per ml leupeptin and 10 ml per
ml pepstatin. Protein concentration was determined using
the Bio-Rad DC Protein Assay kit (Bio-Rad, Hercules, CA,
USA) and separated by SDS-polyacrylamide gel electro-
phoresis Following electrophoresis, proteins on the gel were
transferred to nitrocellulose membranes. After blocking in
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50% Odyssey Infrared Imaging blocking buffer (LI-COR
Biosciences) and 50% phosphate-buffered saline for 60min,
membranes were incubated overnight with primary
antibodies at 4 1C, followed by incubation with infrared
dye-conjugated secondary antibodies at room temperature
for 60min. Membranes were visualized using an Odyssey
Infrared Imaging System (LI-COR Biosciences). Density of
bands was quantified using the Odyssey Infrared Imaging
Software Version 2.1 and using glyceraldehyde 3-phosphate
dehydrogenase as the internal control.
Hematoxylin and eosin staining
Samples of the trunk (first lumbar vertebrae) were cross-
sectioned at 10-mm thickness using a Reichert HistoStat
(Scientific Instruments, Buffalo, NY, USA), stained with
hematoxylin and eosin and examined by light microscopy.
Intraperitoneal glucose tolerance test
Glucose tolerance test was performed on one male offspring
per litter at day 15 and day 60 postnatal. Before the glucose
tolerance test, mice were weighed and fasted overnight with
ad libitum access to water. The tail tip was nicked with a razor
blade, and a small drop of blood was sampled from the tail of
each mouse by gentle stroking. Baseline blood glucose was
measured by the glucose oxidase method using a glucometer
(Bayer Contour, Tarrytown, NY, USA). Following the baseline
sampling, 2 g per kg BW of 20% D-glucose was injected into
the intraperitoneal cavity, and blood glucose measured at
15, 30, 60 and 120min after injection.
Myosin heavy-chain isoform separation
Homogenates from muscle samples were prepared, and
myosin heavy-chain isoform distribution was assessed using
gel electrophoresis, as previously described.33
Real-time PCR for mitochondrial DNA and genomic DNA copy
number
Total DNA was obtained from muscles by an organic solvent
extraction-based method, as described previously.34 DNA
concentration was measured using a Nanodrop 1000 spectro-
photometer (Thermo Scientific, Wilmington, DE, USA), and
subsequently diluted in water to a final concentration of
50ng ml1. Real-time PCR was carried out using an iQ5
RT-PCR detection system (Bio-Rad) using SYBR Green
RT-PCR kit from Bio-Rad and the following cycle parameters:
one cycle of 50 1C for 2min, and 95 1C for 10min, followed
by 40 cycles at 95 1C for 15 s and 60 1C for 60 s. Melting point
dissociation curves and agarose gel electrophoresis were
performed to confirm that only a single product was
amplified. The murine genomic DNA was analyzed by
measuring the single-copy uncoupling protein 2 (UCP2)
gene with primers: GCGTTCTGGGTACCATCCTAAC (forward)
and GCGACCAGCCCATTGTAGA (reverse). Mitochondrial
DNA was analyzed by measuring cytochrome C oxidase II
(Cyt C) mtDNA gene with primers: TTTTCAGGCTTCACCC
TAGATGA (forward) and GAAGAATGTTATGTTTACTCCTAC
GAATATG (reverse). Mitochondrial DNA copy number was
calculated based on the difference in DCt values between
Cyt C and UCP2.35
Blood profile analyses
Serum glucose concentrations were analyzed using Glucose
Assay Kit (Sigma-Aldrich, Saint Louis, Missouri, USA). Serum
triglyceride concentrations were analyzed using Mouse
Serum Triglyceride Determination Kit (Sigma-Aldrich).
Serum insulin concentrations and leptin concentrations
were determined by kits (Linco Research, St Charles, MO,
USA). All experimental assays were performed according to
the manufacturer’s instructions.
Enzyme activity assays
Muscle samples (0.03 g) were homogenized in 1:20 dilution
(wt/vol) of an extraction buffer (0.1M KH2PO4/Na2PO4 and
2mM EDTA, pH 7.2). Citrate synthase and b-hydroxyacyl-
CoA dehydrogenase (b-HAD) activities were assayed spectro-
photometrically, as described elsewhere.36 CS and b-HAD
activity were calculated and reported as mmol per min\g wet
weight of muscle.
Statistical analysis
Each litter was considered as an experimental unit. All data
were expressed as mean±s.e. Data from each time point
(days 1, 15 and 60) were analyzed independently using the
GLM procedure of SAS (SAS Inst. Inc., Cary, NC, USA), and
Tukey’s studentized range test was used for multi-compar-
ison to determine significant differences among means.
Statistical significance was considered as Po0.05.
Results
BW and diet consumption of dams and offspring
There was no difference in maternal BW at the start of
dietary treatments (Supplementary Figure 1). At week 8, BW
of HFD dams and CON dams clearly diverged (Po0.05). By
the end of treatments, BW gain in HFD dams was greater
than CON dams (Po0.05, Supplementary Figure 1). At week
4, the diet intake of HFD mice was lower than CON mice. At
weeks 8 and 12, the diet consumption did not differ between
groups (Supplementary Figure 1).
At weaning (21 days), the OB maternal BWand fat content
were higher in OB and MET groups (Table 1). The circulating
glucose level was higher in OB compared with CON and MET
treatments, but there was no difference in the concentra-
tions of insulin and triglyceride in serum. The leptin content
was higher for both OB and MET compared with CON mice
(Table 1).
The birth weight of offspring born to OB and MET mothers
were heavier than CON mothers (OB mothers, 1.37±0.02 g;
MET mothers, 1.35±0.01g; and CON mothers, 1.26±0.04g),
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whereas there was no difference between OB and MET
mothers (Supplementary Figure 2A). Dietary intake did not
differ substantially between groups (Supplementary Figure
2D). OB offspring showed greater weight gain than CON
offspring throughout the experiment (Figure 2a), whereas
METoffspring was intermediate. At day 60, the gonadal fat of
OB male offspring (1.05±0.17 g) was much heavier than that
of CON offspring (0.57±0.06 g, Po0.05) and tended to be
heavier than that of MET offspring (0.74±0.07 g, P¼0.08;
Supplementary Figures 2B and C).
Maternal metformin administration stimulated AMPK activity
in offspring SM
AMPK was activated in the SM of MET offspring. Phosphor-
ylation of AMPK at Thr 172 in OB offspring SM was reduced
compared with CON mothers (Po0.05 at days 15 and 60,
and P¼0.06 at day 1, Figure 1). The phosphorylation of
AMPK at Thr 172 was rescued in MET offspring SM at the
three time points examined compared with OB offspring SM.
Using western blotting, no significant difference in the
protein content of AMPKa subunit was observed (data not
shown).
Expression of b-catenin and myogenic markers in offspring SM
At day 1, b-catenin protein content tended to be lower in OB
offspring muscle (P¼0.07) compared with CON offspring
muscle, and was increased by metformin administration
(Figure 2). This difference in b-catenin was maintained in the
day-60 gastrocnemius muscle. There was a trend that MyoD
protein expression at days 1 (P¼0.06) and 15 were decreased
in OB offspring SM (P¼0.09), as well as myogenin at day 1
(P¼0.07), indicating that myogenesis might be impaired.
Metformin administration tended to restore MyoD at days 1
and 15 (P¼0.06 and 0.08, respectively), and myogenin
expression at day 15 (P¼0.05, Figure 2).
Adipogenesis in offspring SM
PPAR-g protein expression was much higher in OB offspring
SM compared with CON SM (Po0.05; Figure 2d). Metformin
administration decreased PPAR-g protein expression com-
pared with OB (Po0.05). We next examined the morphology
of offspring muscle. There were no obvious adipocytes visible
in muscle cross-section at day 1 (Figure 3), but at day 15,
mature adipocytes were visible in OB offspring SM; metfor-
min inhibited the formation of intramuscular adipocytes in
offspring SM induced by the maternal HFD (Figure 3).
Maternal metformin administration increased glucose uptake
of offspring
There were no differences in the glucose concentration
among treatments at a single time point (Figure 4). However,
when the total glucose disposal was compared by combining
the incremental area under the curve, offspring of OB dam
had a lower blood glucose disposal rate compared with
those of CON and MET mothers at both days 15 and 60.
The improvement of glucose uptake following metformin
administration was associated with enhanced Akt signaling
(Supplementary Figure 3).
Maternal HFD and metformin administration had no effects
on muscle fiber type distribution in the offspring SM
Myosin heavy-chain isoforms in postnatal mice muscle were
separated (Supplementary Figure 4). There are two develop-
mental myosin heavy-chain isoforms, namely, embryonic
and neonatal myosin heavy-chain isoform, present in new-
born mouse gastrocnemius, which are replaced by adult
isoforms, including type IIA, IIX and IIB by day 14.37 As
shown in Supplementary Figure 4, no difference in muscle
fiber composition was detected among different treatments
at all time points. Also, type I fiber was indistinguishable at
day 60 with this gel electrophoresis method.
Mitochondria DNA copy number and muscle metabolic activity
in the offspring was affected by maternal HFD and metformin
administration
Different muscle fibers have distinct mitochondrial
density. Although we found no difference in muscle fiber
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Figure 1 AMPK phosphorylation in day-1 and -15 offspring hindleg muscle,
and day-60 male offspring gastrocnemius muscle of CON, OB and MET
mothers. Data are expressed as mean±s.e., n¼6. #Po0.05 versus CON;
(#)Po0.1 versus CON; and *Po0.05 versus OB.
Table 1 Maternal BW, fat content and serum profile at weaning
CON OB MET
BW 24.2±1.8 31.5±2.1 28.9±1.5
Body fat content (%) 8.7±0.4 20.0±1.2* 17.9±0.7*,#
Blood profile
Triglyceride (mgml1) 0.96±0.04 1.07±0.06 0.97±0.04
Glucose (mgdl1) 109.0±8.0 137.2±11.8* 107.6±7.2
Insulin (ngml1) 0.86±0.05 1.09±0.11 0.98±0.14
Leptin (ngml1) 2.8±0.3 6.6±0.8* 4.7±0.7*
Abbreviation: BW, body weight. Mean±s.e. *Po0.05 versus CON and
#Po0.05 versus OB. n¼ 6.
Maternal obesity, metformin and offspring muscle
JF Tong et al
4
Nutrition and Diabetes
composition among different treatments, mitochondrial
DNA copy number was decreased in OB offspring at days
15 and 60 (Table 2). Metformin administration to OB dams
increased mitochondrial copy number in the offspring at day
15. Moreover, mitochondrial function in offspring SM was
affected by maternal HFD and metformin administration, as
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Figure 2 Contents of b-catenin, myogenic markers and PPAR-g in day-1 and -15 offspring hindleg muscle, and day-60 male offspring gastrocnemius muscle
of CON, OB and MET mothers. (a) Beta-catenin content; (b) MyoD content; (c) Myogenin content; (d) PPARgamma content. Data are expressed as mean±s.e.,
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Figure 3 Hematoxylin and eosin (H&E) staining of day-1 and -15 offspring muscle of CON, OB and MET mothers. A section of dorsum of the trunk was dissected,
embedded in OCT and frozen in liquid N2. Cryofixed muscle specimens were cross-sectioned at 10-um thickness and stained with H&E, 100 magnification.
(a) CON muscle at day 1; (b) OB muscle at day 1; (c) MET muscle at day 1; (d) CON muscle at day 15; (e) OB muscle at day 15; (f) MET muscle at day 15.
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evidenced by the decrease of citrate synthase activity and
b-HAD activity in OB offspring and restoration of their
activity after maternal metformin administration (Table 2).
Discussion
Both obesity and diabetes are increasing at alarming rates
and among a younger and younger population.1 MO
predisposes offspring to obesity and diabetes, which also
contributes to the increase in obesity, especially in children.9
One explanation is that MO programs hypothalamic regula-
tion of BW and energy homeostasis.38,39 MO in rats does
slightly increase energy intake in offspring.38 Offspring of
obese rat mothers are hyperphagic.40,41 However, in our
study, we only observed a trend toward a higher dietary
intake in OB offspring compared with CON offspring, which
could be because of our small sample size. Also, the diet used
in our study differed from that in the published rat studies,
and offspring may have distinctive preference for sugary and
fatty items in different diets. In addition, strain differences
have been noted in the response to HFDs.41 The observation
that OB offspring showed more weight gain and adiposity
while lacking a significant difference in diet intake suggests
that hyperphagia may not be the only cause of obesity but
differences in basal energy expenditure may also contribute.
SM is the main tissue responsible for glucose and fatty acid
oxidation. Reduction in SM oxidative capacity could lead to
more offspring energy storage and BW gain. Mitochondria
are the main sites of nutrient oxidation to generate ATP.
Citrate synthase is a key enzyme in the tricarboxylic acid
cycle, and b-HAD is a key enzyme in fatty acid oxidation.
Both enzymes are good markers of SM oxidative capacity.42
Our data showed that both mitochondrial content and
function were impaired in OB offspring SM, indicating the
impairment of SM oxidative capacity. Maternal metformin
administration rescued mitochondrial density and function.
In adult muscle, activation of AMPK enhances the oxidative
capacity of SM via a PPAR-g coactivator-1a-mediated
mechanism.43,44 Mitochondrial dysfunction leads to obesity,
insulin resistance and type 2 diabetes.11 Thus, our results
support the notion that low oxidative capacity in muscle has
a role in the etiology of obesity.
AMPK has a critical role in maintaining systemic and
cellular energy status. The growing appreciation that AMPK
coordinates anabolic and catabolic metabolic processes
suggests that it may be an attractive target for preventing
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Figure 4 Glucose tolerance test (GTT) on postnatal day-15 and -60 offspring of CON, OB, and MET mothers. (a) Intraperitoneal GTT in day-15 male offspring
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Table 2 mtDNA copy number, citrate synthase and b-HAD activity in day-1
and -15 offspring hindleg muscle, and day-60 male offspring gastrocnemius
muscle of CON, OB and MET dams
CON OB MET
mtDNA copy numbera
Day 1 315±34 397±29 349±25
Day 15 814±52 680±57* 989±95#
Day 60 1010±61 781±71* 897±137
Citrate synthaseb
Day 1 7.20±0.60 6.23±0.39* 6.56±0.42
Day 15 12.27±0.44 10.28±0.51* 14.08±0.13#
Day 60 27.43±0.86 24.74±0.76* 30.89±0.65#
b-HADb
Day 1 2.54±0.12 2.11±0.20 2.89±0.15
Day 15 4.17±0.38 2.74±0.26* 3.55±0.23#
Day 60 4.01±0.18 3.03±0.31* 4.51±0.45#
Abbreviations: b-HAD, b-hydroxyacyl-CoA dehydrogenase; Cyt C, cytochrome
C oxidase II; mtDNA, mitochondrial DNA; UCP2, uncoupling protein 2.
amtDNA copy number was measured using Cyt C mtDNA gene compared with
genomic UCP2 gene. bActivity was expressed in mmol per min per g wet
weight of muscle. Mean±s.e. *Po0.05 versus CON and #Po0.05 versus OB.
n¼6.
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diabetes and related metabolic diseases. Physiological activa-
tion by exercise or pharmacological activation of AMPK
improves blood glucose disposal, lipid profile and blood
pressure in insulin-resistant humans and rodents, which
indicates that AMPK is an effective drug target in the
therapeutic applications in diabetes and other metabolic
diseases.45 Using a sheep MO model, we detected that MO
downregulates AMPK activity in fetal SM.9 This observation
prompted us to investigate whether activation of AMPK in
fetal and neonatal SM could have a positive effect on its
development and function. In the present study, we elected
to continue metformin administration throughout lactation
and suckling, as SM development during this period in mice
is approximately similar to the development that occurs
from mid to late gestation in sheep and humans. Metformin
readily crosses the placenta.46–48 Metformin is commonly
used to treat type 2 diabetes, and its effect is believed to be
mainly mediated by AMPK.28–30 Our data show that
metformin administration during pregnancy and lactation
increased AMPK activity in offspring SM of obese mothers.
b-Catenin is a key mediator of the canonical Wnt/
b-catenin signaling pathway that is essential for myogenesis,
and blocking the b-catenin pathway reduces the total
number of myocytes.15,16 MyoD and myogenin belong to
the family of muscle-specific transcription factors that
control SM differentiation;49 their expression correlates with
myogenesis. We observed that b-catenin, MyoD and myo-
genin were downregulated in fetal OB SM, which is
consistent with our previous observation in sheep SM.10
PPAR-g is a critical regulator of adipogenesis. Increased
expression of PPAR-g leads to differentiation of pluripotent
cells to adipocytes.20 Our observation of increased PPAR-g in
OB offspring SM indicates that adipogenesis was upregu-
lated, a conclusion confirmed by the presence of increased
numbers of intramuscular adipocytes in OB offspring SM,
detected in OB offspring SM. Maternal metformin adminis-
tration reversed these changes, indicating that metformin is
effective in improving SM development in fetuses and
neonatal mice born to obese mothers. Whether this
beneficial effect is due to the positive impacts of metformin
on maternal whole-body energy metabolism, improved
insulin sensitivity and intrauterine environment or a direct
action on the fetuses of metformin that has crossed the
placenta remains to be clarified.
Currently, metformin administration is avoided during
human pregnancy because of the lack of data about its effects
on fetal development.46,48 Our data show that metformin
administration during pregnancy and lactation has no
obvious negative effect on overall fetal and offspring
development. Progeny from metformin-treated dams
appeared healthy. In addition, our data clearly show that
metformin administration during pregnancy and lactation
improves the development of fetal SM of obese mothers,
which may provide a promising strategy to prevent the fetal-
programming effect of obesity during pregnancy on fetal and
offspring SM development.
Conflict of interest
The authors declared no conflict of interest.
Acknowledgements
The research is supported by the National Institute of Child
Health & Human Development: R01HD067449, and the
National Center for Research Resources of NIH and the
Wyoming INBRE: P20RR016474, and USDA-NRI-2008-
35206-18826.
References
1 Petersen KF, Dufour S, Shulman GI. Decreased insulin-stimulated
ATP synthesis and phosphate transport in muscle of insulin-
resistant offspring of type 2 diabetic parents. PLoS Med 2005; 2:
e233.
2 Galtier F, Raingeard I, Renard E, Boulot P, Bringer J. Optimizing
the outcome of pregnancy in obese women: from pregestational
to long-term management. Diabetes Metab 2008; 34: 19–25.
3 Siega-Riz AM, Siega-Riz AM, Laraia B. The implications of
maternal overweight and obesity on the course of pregnancy
and birth outcomes. Matern Child Health J 2006; 10: 153–156.
4 Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N
et al. Reduced mitochondrial density and increased IRS-1 serine
phosphorylation in muscle of insulin-resistant offspring of type 2
diabetic parents. J Clin Invest 2005; 115: 3587–3593.
5 Fowden AL, Ward JW, Wooding FP, Forhead AJ, Constancia M.
Programming placental nutrient transport capacity. J Physiol
2006; 572: 5–15.
6 Nathanielsz PW. Animal models that elucidate basic principles of
the developmental origins of adult diseases. Ilar J 2006; 47: 73–82.
7 Barker DJ. Fetal programming of coronary heart disease. Trends
Endocrinol Metab 2002; 13: 364–368.
8 Armitage JA, Khan IY, Taylor PD, Nathanielsz PW, Poston L.
Developmental programming of the metabolic syndrome by
maternal nutritional imbalance: how strong is the evidence from
experimental models in mammals? J Physiol 2004; 561: 355–377.
9 Zhu MJ, Han B, Tong J, Ma C, Kimzey JM, Underwood KR et al.
AMP-activated protein kinase signalling pathways are down
regulated and skeletal muscle development impaired in fetuses
of obese, over-nourished sheep. J Physiol 2008; 586: 2651–2664.
10 Tong JF, Yan X, Zhu MJ, Ford SP, Nathanielsz PW, Du M. Maternal
obesity downregulates myogenesis and beta-catenin signaling in
fetal skeletal muscle. Am J Physiol Endocrinol Metab 2009; 296:
E917–E924.
11 Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2
diabetes. Science 2005; 307: 384–387.
12 Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S, Vaag AA.
Low birthweight is associated with specific changes in muscle
insulin-signalling protein expression. Diabetologia 2005; 48: 547–552.
13 Selak MA, Storey BT, Peterside I, Simmons RA. Impaired oxidative
phosphorylation in skeletal muscle of intrauterine growth-
retarded rats. Am J Physiol Endocrinol Metab 2003; 285: E130–E137.
14 Du M, Yan X, Tong JF, Zhao J, Zhu MJ. Maternal obesity,
inflammation, and fetal skeletal muscle development. Biol Reprod
2010; 82: 4–12.
15 Mermelstein CS, Portilho DM, Mendes FA, Costa ML, Abreu JG.
Wnt/beta-catenin pathway activation and myogenic differentia-
tion are induced by cholesterol depletion. Differentiation 2007;
75: 184–192.
16 Armstrong DD, Esser KA. Wnt/beta-catenin signaling activates
growth-control genes during overload-induced skeletal muscle
hypertrophy. Am J Physiol 2005; 289: C853–C859.
Maternal obesity, metformin and offspring muscle
JF Tong et al
7
Nutrition and Diabetes
17 Cossu G, Borello U. Wnt signaling and the activation of
myogenesis in mammals. EMBO J 1999; 18: 6867–6872.
18 Yamanouchi K, Hosoyama T, Murakami Y, Nishihara M.
Myogenic and adipogenic properties of goat skeletal muscle stem
cells. J Reprod Dev 2007; 53: 51–58.
19 Pan W, Jia Y, Wang J, Tao D, Gan X, Tsiokas L et al. Beta-catenin
regulates myogenesis by relieving I-mfa-mediated suppression of
myogenic regulatory factors in P19 cells. Proc Natl Acad Sci USA
2005; 102: 17378–17383.
20 Spiegelman BM, Puigserver P, Wu Z. Regulation of adipogenesis
and energy balance by PPARgamma and PGC-1. Int J Obes Relat
Metab Disord 2000; 24(Suppl 4): S8–S10.
21 Aguiari P, Leo S, Zavan B, Vindigni V, Rimessi A, Bianchi K et al.
High glucose induces adipogenic differentiation of muscle-
derived stem cells. Proc Natl Acad Sci USA 2008; 105: 1226–1231.
22 Hardie DG. AMP-activated protein kinase: a key system mediat-
ing metabolic responses to exercise. Med Sci Sports Exerc 2004; 36:
28–34.
23 Hardie DG. New roles for the LKB1-AMPK pathway. Curr Opin
Cell Biol 2005; 17: 167–173.
24 Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 50-AMP-
activated protein kinase phosphorylates IRS-1 on Ser-789 in
mouse C2C12 myotubes in response to 5-aminoimidazole-4-
carboxamide riboside. J Biol Chem 2001; 276: 46912–46916.
25 Dagon Y, Avraham Y, Berry EM. AMPK activation regulates
apoptosis, adipogenesis, and lipolysis by eIF2alpha in adipocytes.
Biochem Biophys Res Commun 2006; 340: 43–47.
26 Habinowski SA, Witters LA. The effects of AICAR on adipocyte
differentiation of 3T3-L1 cells. Biochem Biophys Res Commun 2001;
286: 852–856.
27 Giri S, Rattan R, Haq E, Khan M, Yasmin R, Won JS et al. AICAR
inhibits adipocyte differentiation in 3T3L1 and restores meta-
bolic alterations in diet-induced obesity mice model. Nutr Metab
(Lond) 2006; 3: 31.
28 Hawley SA, Gadalla AE, Olsen GS, Hardie DG. The antidiabetic
drug metformin activates the AMP-activated protein kinase
cascade via an adenine nucleotide-independent mechanism.
Diabetes 2002; 51: 2420–2425.
29 Lee JO, Lee SK, Jung JH, Kim JH, You GY, Kim SJ et al. Metformin
induces Rab4 through AMPK and modulates GLUT4 transloca-
tion in skeletal muscle cells. J Cell Physiol 2010; 226: 974–981.
30 Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles IV WG,
Schlattner U et al. Activation of the AMP-activated protein kinase
by the anti-diabetic drug metformin in vivo. Role of mito-
chondrial reactive nitrogen species. J Biol Chem 2004; 279:
43940–43951.
31 Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL et al.
Metformin therapy in a transgenic mouse model of Huntington’s
disease. Neurosci Lett 2007; 411: 98–103.
32 Folch J, Lees M, Sloane Stanley GH. A simple method for the
isolation and purification of total lipids from animal tissues. J Biol
Chem 1957; 226: 497–509.
33 Underwood KR, Tong J, Zhu MJ, Shen QW, Means WJ, Ford SP
et al. Relationship between kinase phosphorylation, muscle fiber
typing, and glycogen accumulation in longissimus muscle of beef
cattle with high and low intramuscular fat. J Agric Food Chem
2007; 55: 9698–9703.
34 Guo W, Jiang L, Bhasin S, Khan SM, Swerdlow RH. DNA
extraction procedures meaningfully influence qPCR-based
mtDNA copy number determination. Mitochondrion 2009; 9:
261–265.
35 Sparks LM, Xie H, Koza RA, Mynatt R, Hulver MW, Bray GA et al.
A high-fat diet coordinately downregulates genes required for
mitochondrial oxidative phosphorylation in skeletal muscle.
Diabetes 2005; 54: 1926–1933.
36 Call JA, Voelker KA, Wolff AV, McMillan RP, Evans NP, Hulver MW
et al. Endurance capacity in maturing mdx mice is markedly
enhanced by combined voluntary wheel running and green tea
extract. J Appl Physiol 2008; 105: 923–932.
37 Agbulut O, Noirez P, Beaumont F, Butler-Browne G. Myosin heavy
chain isoforms in postnatal muscle development of mice.
Biol Cell 2003; 95: 399–406.
38 Page KC, Malik RE, Ripple JA, Anday EK. Maternal and
postweaning diet interaction alters hypothalamic gene expres-
sion and modulates response to a high-fat diet in male offspring.
Am J Physiol Regul Integr Comp Physiol 2009; 297: R1049–R1057.
39 Kirk SL, Samuelsson AM, Argenton M, Dhonye H, Kalamatianos T,
Poston L et al. Maternal obesity induced by diet in rats permanently
influences central processes regulating food intake in offspring. PLoS
One 2009; 4: e5870.
40 Nivoit P, Morens C, Van Assche FA, Jansen E, Poston L, Remacle C
et al. Established diet-induced obesity in female rats leads
to offspring hyperphagia, adiposity and insulin resistance.
Diabetologia 2009; 52: 1133–1142.
41 Samuelsson AM, Matthews PA, Argenton M, Christie MR,
McConnell JM, Jansen EH et al. Diet-induced obesity in female
mice leads to offspring hyperphagia, adiposity, hypertension, and
insulin resistance: a novel murine model of developmental
programming. Hypertension 2008; 51: 383–392.
42 Bruce CR, Anderson MJ, Carey AL, Newman DG, Bonen A,
Kriketos AD et al.Muscle oxidative capacity is a better predictor of
insulin sensitivity than lipid status. J Clin Endocrinol Metab 2003;
88: 5444–5451.
43 Atherton PJ, Babraj J, Smith K, Singh J, Rennie MJ, Wackerhage H.
Selective activation of AMPK-PGC-1alpha or PKB-TSC2-mTOR
signaling can explain specific adaptive responses to endurance or
resistance training-like electrical muscle stimulation. FASEB J
2005; 19: 786–788.
44 Suwa M, Egashira T, Nakano H, Sasaki H, Kumagai S. Metformin
increases the PGC-1alpha protein and oxidative enzyme activities
possibly via AMPK phosphorylation in skeletal muscle in vivo.
J Appl Physiol 2006; 101: 1685–1692.
45 Hardie DG. Biochemistry. Balancing cellular energy. Science 2007;
315: 1671–1672.
46 Feig DS. Metformin therapy for gestational diabetes mellitus: are
we there yet? Nat Clin Pract Endocrinol Metab 2008; 4: 654–655.
47 Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, Hoffman A.
Carrier-mediated transport of metformin across the human
placenta determined by using the ex vivo perfusion of the
placental cotyledon model. Prenat Diagn 2008; 28: 544–548.
48 Paglia MJ, Coustan DR. The use of oral antidiabetic medications
in gestational diabetes mellitus. Curr Diab Rep 2009; 9: 287–290.
49 Sabourin LA, Rudnicki MA. The molecular regulation of myogen-
esis. Clin Genet 2000; 57: 16–25.
This work is licensed under the Creative
CommonsAttribution-NonCommercial-Share
Alike 3.0 Unported License. To view a copy of this
license, visit http://creativecommons.org/licenses/
by-nc-sa/3.0/
Supplementary Information accompanies the paper on the Nutrition and Diabetes website (http://www.nature.com/nutd)
Maternal obesity, metformin and offspring muscle
JF Tong et al
8
Nutrition and Diabetes
